Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome.

Meintjes G, Wilkinson RJ, Morroni C, Pepper DJ, Rebe K, Rangaka MX, Oni T, Maartens G.

AIDS. 2010 Sep 24;24(15):2381-90. doi: 10.1097/QAD.0b013e32833dfc68.

2.

Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.

Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Tadokera R, Conesa-Botella A, Seldon R, Rangaka MX, Rebe K, Pepper DJ, Morroni C, Colebunders R, Maartens G, Wilkinson RJ.

Am J Respir Crit Care Med. 2012 Aug 15;186(4):369-77. doi: 10.1164/rccm.201201-0094OC. Epub 2012 Jun 14.

3.

Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial).

Stek C, Schutz C, Blumenthal L, Thienemann F, Buyze J, Nöstlinger C, Ravinetto R, Wouters E, Colebunders R, Maartens G, Wilkinson RJ, Lynen L, Meintjes G.

JMIR Res Protoc. 2016 Aug 29;5(3):e173. doi: 10.2196/resprot.6046.

4.

Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome.

Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Seldon R, Chegou NN, Maartens G, Rangaka MX, Rebe K, Walzl G, Wilkinson RJ.

Eur Respir J. 2011 May;37(5):1248-59. doi: 10.1183/09031936.00091010. Epub 2010 Sep 3.

5.

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.

Laureillard D, Marcy O, Madec Y, Chea S, Chan S, Borand L, Fernandez M, Prak N, Kim C, Dim B, Nerrienet E, Sok T, Delfraissy JF, Goldfeld AE, Blanc FX; CAMELIA (ANRS 1295 – CIPRA KH001) Study Team.

AIDS. 2013 Oct 23;27(16):2577-86. doi: 10.1097/01.aids.0000432456.14099.c7.

PMID:
24096631
6.

Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series.

Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX, Oni T, Wilkinson RJ, Meintjes G.

Clin Infect Dis. 2009 Jun 1;48(11):e96-107. doi: 10.1086/598988.

PMID:
19405867
7.

Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection.

Worodria W, Menten J, Massinga-Loembe M, Mazakpwe D, Bagenda D, Koole O, Mayanja-Kizza H, Kestens L, Mugerwa R, Reiss P, Colebunders R; TB-IRIS Study Group.

Antivir Ther. 2012;17(5):841-8. doi: 10.3851/IMP2108. Epub 2012 Apr 27.

PMID:
22543224
8.

Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.

Luetkemeyer AF, Kendall MA, Nyirenda M, Wu X, Ive P, Benson CA, Andersen JW, Swindells S, Sanne IM, Havlir DV, Kumwenda J; Adult AIDS Clinical Trials Group A5221 Study Team.

J Acquir Immune Defic Syndr. 2014 Apr 1;65(4):423-8. doi: 10.1097/QAI.0000000000000030.

9.

Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children.

Van Rie A, Sawry S, Link-Gelles R, Madhi S, Fairlie L, Verwey C, Mahomed N, Murdoch D, Moultrie H.

Pediatr Pulmonol. 2016 Feb;51(2):157-64. doi: 10.1002/ppul.23221. Epub 2015 Jun 14.

10.

A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition.

Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S, Miglani S, Gupta D.

Indian J Med Res. 2010 Jun;131:804-8.

11.

Treatment for tuberculosis-associated immune reconstitution inflammatory syndrome in 34 HIV-infected patients.

Breton G, Bourgarit A, Pavy S, Bonnet D, Martinez V, Duval X, Longuet P, Abgrall S, Simon A, Leport C; Paradox-TB Study Group.

Int J Tuberc Lung Dis. 2012 Oct;16(10):1365-70. doi: 10.5588/ijtld.11.0693. Erratum in: Int J Tuberc Lung Dis. 2012 Dec;16(12):1712. ANRS-EP21 (Agence Nationale de Recherche sur le Sida) Paradox TB Study Group [corrected to Paradox-TB Study Group]. Int J Tuberc Lung Dis. 2014 Jun;18(6):754. Elmarsafy, S [corrected to El Marsafy, S].

PMID:
23107635
12.

Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis.

Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G.

Future Microbiol. 2015;10(6):1077-99. doi: 10.2217/fmb.15.9. Review.

PMID:
26059627
13.

The clinical pattern, prevalence, and factors associated with immune reconstitution inflammatory syndrome in Ugandan children.

Orikiiriza J, Bakeera-Kitaka S, Musiime V, Mworozi EA, Mugyenyi P, Boulware DR.

AIDS. 2010 Aug 24;24(13):2009-17. doi: 10.1097/QAD.0b013e32833b260a.

14.

Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.

Michailidis C, Pozniak AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG.

Antivir Ther. 2005;10(3):417-22.

PMID:
15918332
15.

Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy.

Elliott JH, Vohith K, Saramony S, Savuth C, Dara C, Sarim C, Huffam S, Oelrichs R, Sophea P, Saphonn V, Kaldor J, Cooper DA, Chhi Vun M, French MA.

J Infect Dis. 2009 Dec 1;200(11):1736-45. doi: 10.1086/644784.

PMID:
19874177
16.

Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.

Haddow LJ, Moosa MY, Mosam A, Moodley P, Parboosing R, Easterbrook PJ.

PLoS One. 2012;7(11):e40623. doi: 10.1371/journal.pone.0040623. Epub 2012 Nov 12.

17.

Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.

Mfinanga SG, Kirenga BJ, Chanda DM, Mutayoba B, Mthiyane T, Yimer G, Ezechi O, Connolly C, Kapotwe V, Muwonge C, Massaga J, Sinkala E, Kohi W, Lyantumba L, Nyakoojo G, Luwaga H, Doulla B, Mzyece J, Kapata N, Vahedi M, Mwaba P, Egwaga S, Adatu F, Pym A, Joloba M, Rustomjee R, Zumla A, Onyebujoh P.

Lancet Infect Dis. 2014 Jul;14(7):563-71. doi: 10.1016/S1473-3099(14)70733-9. Epub 2014 May 5. Erratum in: Lancet Infect Dis. 2014 Jul;14(7):548.

PMID:
24810491
18.

Management of the immune reconstitution inflammatory syndrome.

Meintjes G, Scriven J, Marais S.

Curr HIV/AIDS Rep. 2012 Sep;9(3):238-50. doi: 10.1007/s11904-012-0129-5. Review.

PMID:
22752438
19.

Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome.

Conesa-Botella A, Loembé MM, Manabe YC, Worodria W, Mazakpwe D, Luzinda K, Mayanja-Kizza H, Miri M, Mbabazi O, Koole O, Kestens L, Colebunders R; TB IRIS Group.

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):463-8. doi: 10.1097/QAI.0b013e31823801de.

PMID:
21963941
20.

Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.

Chakrabarti LA, Boucherie C, Bugault F, Cumont MC, Roussillon C, Breton G, Patey O, Chêne G, Richert L, Lortholary O; ANRS 129 BKVIR-CYTOK STUDY GROUP.

AIDS. 2014 Jul 17;28(11):1593-602. doi: 10.1097/QAD.0000000000000311.

Supplemental Content

Support Center